Literature DB >> 33545406

Lifetime impact of achondroplasia: Current evidence and perspectives on the natural history.

Julie Hoover-Fong1, Moira S Cheung2, Virginia Fano3, Lars Hagenas4, Jacqueline T Hecht5, Penny Ireland6, Melita Irving2, Klaus Mohnike7, Amaka C Offiah8, Ericka Okenfuss9, Keiichi Ozono10, Cathleen Raggio11, Louise Tofts12, Dominique Kelly13, Renée Shediac13, Wayne Pan13, Ravi Savarirayan14.   

Abstract

Achondroplasia, the most common form of disproportionate short stature, is caused by a variant in the fibroblast growth factor receptor 3 (FGFR3) gene. Advances in drug treatment for achondroplasia have underscored the need to better understand the natural history of this condition. This article provides a critical review and discussion of the natural history of achondroplasia based on current literature evidence and the perspectives of clinicians with extensive knowledge and practical experience in managing individuals with this diagnosis. This review draws evidence from recent and ongoing longitudinal natural history studies, supplemented with relevant cross-sectional studies where longitudinal research is lacking, to summarize the current knowledge on the nature, incidence, chronology, and interrelationships of achondroplasia-related comorbidities across the lifespan. When possible, data related to adults are presented separately from data specific to children and adolescents. Gaps in knowledge regarding clinical care are identified and areas for future research are recommended and discussed.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Achondroplasia; Cervicomedullary decompression; Fibroblast growth factor receptor 3 (FGFR3); Foramen magnum stenosis; Genu varum; Natural history; Skeletal dysplasia

Year:  2021        PMID: 33545406     DOI: 10.1016/j.bone.2021.115872

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  9 in total

1.  [Clinical features and FGFR3 mutations of children with achondroplasia].

Authors:  Hui-Qin Zhang; Dong-Ying Tao; Jing-Jing Zhang; Huan-Hong Niu; Jian-Feng Luo; Sheng-Quan Cheng
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-04-15

2.  Literature review and expert opinion on the impact of achondroplasia on medical complications and health-related quality of life and expectations for long-term impact of vosoritide: a modified Delphi study.

Authors:  Ravi Savarirayan; Wagner Baratela; Thomas Butt; Valérie Cormier-Daire; Melita Irving; Bradley S Miller; Klaus Mohnike; Keiichi Ozono; Ron Rosenfeld; Angelo Selicorni; Dominic Thompson; Klane K White; Michael Wright; Svein O Fredwall
Journal:  Orphanet J Rare Dis       Date:  2022-06-13       Impact factor: 4.303

Review 3.  Impact of achondroplasia on Latin American patients: a systematic review and meta-analysis of observational studies.

Authors:  Virginia Fano; Chong A Kim; Pablo Rosselli; Regina El Dib; Renée Shediac; Tatiana Magalhães; Debora Mesojedovas; Juan Llerena
Journal:  Orphanet J Rare Dis       Date:  2022-01-04       Impact factor: 4.123

4.  Lower Back Pain Heralding Cauda Equina Syndrome in a Patient With Achondroplasia.

Authors:  Ting-Yu Lin; Chun-Sheng Ho; Ke-Vin Chang; Wei-Ting Wu; Levent Ozcakar
Journal:  Cureus       Date:  2022-02-19

5.  Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies.

Authors:  Ravi Savarirayan; Josep Maria De Bergua; Paul Arundel; Helen McDevitt; Valerie Cormier-Daire; Vrinda Saraff; Mars Skae; Borja Delgado; Antonio Leiva-Gea; Fernando Santos-Simarro; Jean Pierre Salles; Marc Nicolino; Massimiliano Rossi; Peter Kannu; Michael B Bober; John Phillips; Howard Saal; Paul Harmatz; Christine Burren; Garrett Gotway; Terry Cho; Elena Muslimova; Richard Weng; Daniela Rogoff; Julie Hoover-Fong; Melita Irving
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-03-21       Impact factor: 5.346

6.  Key measurement concepts and appropriate clinical outcome assessments in pediatric achondroplasia clinical trials.

Authors:  Natalie V J Aldhouse; Helen Kitchen; Chloe Johnson; Chris Marshall; Hannah Pegram; Sheryl Pease; Sam Collins; Christine L Baker; Katherine Beaverson; Chandler Crews; Jill Massey; Kathleen W Wyrwich
Journal:  Orphanet J Rare Dis       Date:  2022-05-07       Impact factor: 4.303

7.  Experiences of children and adolescents living with achondroplasia and their caregivers.

Authors:  Renée Shediac; Olga Moshkovich; Heather Gerould; Rachel Ballinger; Agnes Williams; M Alex Bellenger; Jennifer Quinn; Julie Hoover-Fong; Klaus Mohnike; Ravi Savarirayan; Dominique Kelly
Journal:  Mol Genet Genomic Med       Date:  2022-02-09       Impact factor: 2.183

8.  Medical complications in children with achondroplasia.

Authors:  Jennifer A Armstrong; Verity Pacey; Louise J Tofts
Journal:  Dev Med Child Neurol       Date:  2022-03-02       Impact factor: 4.864

9.  Optimising care and follow-up of adults with achondroplasia.

Authors:  Svein Fredwall; Yana Allum; Moeenaldeen AlSayed; Inês Alves; Tawfeg Ben-Omran; Silvio Boero; Valerie Cormier-Daire; Encarna Guillen-Navarro; Melita Irving; Christian Lampe; Mohamad Maghnie; Klaus Mohnike; Geert Mortier; Sérgio B Sousa; Michael Wright
Journal:  Orphanet J Rare Dis       Date:  2022-08-20       Impact factor: 4.303

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.